IRIS

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib / White, Dl; Radich, J; Soverini, S; Saunders, Va; Frede, Ak; Dang, P; Cilloni, D; Lin, P; Mongay, L; Woodman, R; Manley, P; Slader, C; Kim, Dw; Pane, Fabrizio; Martinelli, G; Saglio, G; Hughes, Tp. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 97:6(2012), pp. 907-914. [10.3324/haematol.2011.056457]

Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.

PANE, FABRIZIO;
2012
2012
HAEMATOLOGICA
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib / White, Dl; Radich, J; Soverini, S; Saunders, Va; Frede, Ak; Dang, P; Cilloni, D; Lin, P; Mongay, L; Woodman, R; Manley, P; Slader, C; Kim, Dw; Pane, Fabrizio; Martinelli, G; Saglio, G; Hughes, Tp. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 97:6(2012), pp. 907-914. [10.3324/haematol.2011.056457]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/573886
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 47
social impact